Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VipoCal
- Development stage
- Unknown
- Lead developer
- Royal Medicalink Pharmalab
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
VipoCal is a calcium and vitamin D3 supplement developed and marketed by the Indonesian company Royal Medicalink Pharmalab. Each film-coated caplet contains 750 mg of *Lithothamnium* sp., a red marine algae that provides a natural, bioavailable source of calcium and other trace minerals, along with 400 IU of Vitamin D3 (cholecalciferol). Classified as a traditional medicine and consumer health product, VipoCal is indicated to support bone health and meet daily requirements for calcium and vitamin D. It is typically administered as one caplet daily and is available in boxes containing 3 strips of 10 caplets each.
- Brand names
- VipoCalVipaCal
02
Targets
VDR (Vitamin D receptor)
Beyond the preview
Go deeper on VipoCal.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VipoCal.